A new pilot clinical study will explore the safety and effectiveness of 2 anti-canine monoclonal antibodies on solid tumors ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

A “MOLECULAR shield” placed in the nose could prevent hay fever symptoms, a study suggests. Scientists have engineered an ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

RSV compared to those who did not get BEYFORTUS, per new post-hoc analysis MORRISTOWN, N.J., July 22, 2025 /PRNewswire/ -- The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...